In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B results in $35mm for Alnara

Executive Summary

Alnara Pharmaceuticals (developing oral protein therapeutics for metabolic disorders) raised $35mm in its Series B financing led by first-time backer MPM Capital, which was joined by returning shareholders Third Rock Ventures, Frazier Healthcare, and Bessemer Venture Partners. The company will use some of the funds to help gain approval for and launch its liprotamase to treat exocrine pancreatic insufficiency, and for ongoing development of a liprotamase formulation aimed at cystic fibrosis in pediatric patients. A member of MPM will take a seat on Alnara's board.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies